School of Nursing, Anhui Medical University, Hefei, Anhui, China.
Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China; Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.
Int Immunopharmacol. 2023 May;118:110128. doi: 10.1016/j.intimp.2023.110128. Epub 2023 Apr 4.
Receptor Interacting Serine/Threonine Kinase 2 (RIPK2) is an essential regulator of the inflammatory process and immune response. In innate immunity, the NOD-RIPK2 signaling axis is an important pathway that directly mediates inflammation and immune response. In adaptive immunity, RIPK2 may affect T cell proliferation, differentiation and cellular homeostasis thereby involving T cell-driven autoimmunity, but the exact mechanism remains unclear. Recent advances suggest a key role of RIPK2 in diverse autoimmune diseases (ADs) such as inflammatory bowel diseases, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, and Behcet's disease. This review aims to provide valuable therapeutic direction for ADs by focusing on the function and modulation of RIPK2 in innate and adaptive immunity, its involvement with various ADs and the application of RIPK2-related drugs in ADs. We raise the notion that drug targeting RIPK2 could be a promising therapeutic strategy for the treatment of ADs, though much work remains to be done for clinical application.
受体相互作用丝氨酸/苏氨酸激酶 2（RIPK2）是炎症过程和免疫反应的重要调节剂。在先天免疫中，NOD-RIPK2 信号轴是直接介导炎症和免疫反应的重要途径。在适应性免疫中，RIPK2 可能影响 T 细胞的增殖、分化和细胞稳态，从而参与 T 细胞驱动的自身免疫，但确切的机制尚不清楚。最近的研究进展表明，RIPK2 在多种自身免疫性疾病（AD）中具有关键作用，如炎症性肠病、类风湿关节炎、多发性硬化症、系统性红斑狼疮和贝赫切特病。本综述通过关注 RIPK2 在先天和适应性免疫中的功能和调节、其与各种 AD 的关系以及 RIPK2 相关药物在 AD 中的应用，旨在为 AD 提供有价值的治疗方向。我们提出这样的观点，即针对 RIPK2 的药物可能是治疗 AD 的一种有前途的治疗策略，但仍有许多工作需要为临床应用完成。
